Direct thrombin inhibitor-bivalirudin functionalized plasma polymerized allylamine coating for improved biocompatibility of vascular devices

Biomaterials

Volumn 33, Issue 32, 2012, Pages 7959-7971

  Yang, Zhilu ^a   Tu, Qiufen ^a   Maitz, Manfred F ^a,b   Zhou, Shuo ^a   Wang, Jin ^a   Huang, Nan ^a  

^a SOUTHWEST JIAOTONG UNIVERSITY   (China)

^b LEIBNIZ INSTITUTE OF POLYMER RESEARCH DRESDEN   (Germany)

Author keywords

Bivalirudin; Endothelial cell; Hemocompatibility; Re endothelialization; Surface modification; Vascular devices

Indexed keywords

316 L STAINLESS STEEL; ACUTE CORONARY SYNDROMES; ALLYL AMINE; BIVALIRUDIN; CLINICAL APPLICATION; CLOTTING TIME; DIABETIC PATIENT; DIRECT THROMBIN INHIBITOR; FUNCTIONALIZED; HEMOCOMPATIBILITY; HEMODIALYSIS MEMBRANES; IN-VIVO; RE-ENDOTHELIALIZATION; REAL TIME MONITORING; RELEASE OF NITRIC OXIDE; THROMBUS FORMATION; VASCULAR DEVICES; VASCULAR GRAFTS;

BIOCOMPATIBILITY; CELL ADHESION; DIALYSIS; DRUG PRODUCTS; ENDOTHELIAL CELLS; ENZYMES; GRAFTS; INFRARED SPECTROSCOPY; NITRIC OXIDE; ORGANIC POLYMERS; OXYGENATION; PHOTOELECTRONS; SURFACE TREATMENT; X RAY PHOTOELECTRON SPECTROSCOPY;

COATINGS;

ACTIN; ALLYLAMINE; FIBRINOGEN; GOLD; HIRULOG; NITRIC OXIDE; PALLADIUM; PROSTACYCLIN; STAINLESS STEEL; THROMBIN; THROMBIN INHIBITOR; WARFARIN;

ANIMAL EXPERIMENT; ANTICOAGULATION; APOPTOSIS; ARTICLE; BARE METAL STENT; BIOCOMPATIBILITY; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; BLOOD VESSEL GRAFT; CARDIOVASCULAR EQUIPMENT; CATHETER; CELL ADHESION; CELL CULTURE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; CORONARY STENT; DEVICES; DIALYSIS MEMBRANE; DOG; DRUG ELUTING STENT; ENDOTHELIUM CELL; FEMORAL ARTERY; FILM; HEMOCOMPATIBILITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MATERIAL COATING; NONHUMAN; OXYGENATOR; PLASMA; POLYMERIZATION; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; SCANNING ELECTRON MICROSCOPY; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE STRUCTURE; TUBE; UMBILICAL VEIN; X RAY PHOTOELECTRON SPECTROSCOPY;

ALLYLAMINE; AMINO ACID SEQUENCE; ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD VESSEL PROSTHESIS; CELL ADHESION; CELL PROLIFERATION; COATED MATERIALS, BIOCOMPATIBLE; DOGS; ENDOTHELIAL CELLS; HIRUDINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POLYMERIZATION; RECOMBINANT PROTEINS; STAINLESS STEEL; SURFACE PROPERTIES; THROMBIN;

EID: 84865546704     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.07.050     Document Type: Article

References (62)

1. Di Nisio M., Middeldorp S., Buller H.R. Direct thrombin inhibitors. N Engl J Med 2005, 353:1028-1040.
2. Rosenberg R.D., Damus P.S. The role of heparin in the thrombin-antithrombin III reaction. J Biol Chem 1973, 248:6490-6505.
3. Li G.C., Yang P., Qin W., Maitz M.F., Zhou S., Huang N. The effect of coimmobilizing heparin and fibronectin on titanium on hemocompatibility and endothelialization. Biomaterials 2011, 32:4691-4703.
4. Yang Z.L., Wang J., Luo R.F., Maitz M.F., Jing F.J., Sun H., et al. The covalent immobilization of heparin to pulsed-plasma polymeric allylamine films on 316L stainless steel and the resulting effects on hemocompatibility. Biomaterials 2010, 31:2072-2083.
5. Gong F.R., Cheng X.Y., Wang S.F., Zhao Y.C., Gao Y., Cai H.B. Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents. Acta Biomater 2010, 6:534-546.
6. Hirsh J., Anand S.S., Halperin J.L., Fuster V. Guide to anticoagulant therapy: heparin a statement for healthcare professionals from the American Heart Association. Circulation 2001, 103:2994-3018.
7. Swart C.A., Nijmeyer B., Roelofs J.M., Sixma J.J. Kinetics of intravenously administered heparin in normal humans. Blood 1982, 60:1251-1258.
8. Weitz J.I., Leslie B., Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998, 97:544-552.
9. Maitz M.F., Sperling C., Werner C. Immobilization of the irreversible thrombin inhibitor D-Phe-Pro-Argchloromethylketone: a concept for hemocompatible surfaces. J Biomed Mater Res A 2010, 3:905-912.
10. Freitas S.C., Abarbosa M., Martins M.C.L. The effect of immobilization of thrombin inhibitors onto self-assembled monolayers on the adsorption and activity of thrombin. Biomaterials 2010, 31:3772-3780.
11. Lefevre G., Duval M., Gauron S., Brookman L.J., Rolan P.E., Morris T.M. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther 1997, 62:50-59.
12. Anand S.X., Kim M.C., Kamran M. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007, 100:417-424.
13. Weitz J.I., Hudoba M., Messel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
14. Angiomax (bivalirudin) prescribing information December 6, 2005, The Medicines Company, Parsippany, NJ.
15. Stone G.W., McLaurin B.T., Cox D.A. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203-2216.
16. Weitz J.I., Bates S.M. Acute coronary syndromes: a focus on thrombin. J Invasive Cardiol 2002, 14(Suppl. B):2B-7B.
17. Hamerli P., Weigel T., Groth T., Paul D. Surface properties of and cell adhesion onto allylamine-plasma-coated polyethylenterephtalat membranes. Biomaterials 2003, 24:3989-3999.
18. Finke B., Luethen F., Schroeder K., Mueller P.D., Bergemann C., Frantc M., et al. The effect of positively charged plasma polymerization on initial osteoblastic focal adhesion on titanium surfaces. Biomaterials 2007, 28:4521-4534.
19. Petersen J., Bechara R., Bardon J., Fouquet T., Ziarelli F., Daheron L., et al. Atmospheric plasma deposition process: a versatile tool for the design of tunable siloxanes-based plasma polymer films. Plasma Process Polym 2011, 10:895-903.
20. 2 coating for covalent immobilization of heparin. Plasma Process Polym 2011, 8:850-858.
21. Hermanson G.T. Bioconjugate techniques 1996, Academic Press, San Diego, CA. 1st ed.
22. Yang Z.L., Lei X.J., Wang J., Luo R.F., He T.T., Sun H., et al. A novel technique toward bipolar films containing alternating nano-layers of allylamine and acrylic acid plasma polymers for biomedical application. Plasma Process Polym 2011, 8:208-214.
23. Cans A.-S., Höök F., Shupliakov O., Ewing A.G., Eriksson P.S., Brodin L., et al. Measurement of dynamics of exocytosis and vesicle retrieval at cell populations using a quartz crystal microbalance. Anal Chem 2001, 73:5805-5811.
24. Höök F., Kasemo B., Nylander T., Fant C., Cott K., Elwing H. Variations in coupled water, viscoelastic properties, and film thickness of a Mefp-1 Protein film during adsorption and crosslinking: a quartz crystal microbalance with dissipation monitoring, ellipsometry, and surface plasmon resonance study. Anal Chem 2001, 73:5796-5804.
25. Voinova M.V., Rodahl M., Jonson M., Kasemo B. Viscoelastic acoustic response of layered polymer films at fluid solid interfaces: continuum mechanics approach. Phys Scr 1999, 59:391-396.
26. Marx K.A. Quartz crystal microbalance: a useful tool for studying thin polymer films and complex biomolecular systems at the solution-surface interface. Biomacromolecules 2003, 4:1099-1120.
27. Davie E.W., Fujikawa K. Basic mechanisms in blood coagulation. Annu Rev Biochem 1975, 44:799-829.
28. McEver R.P., Martin N.M. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J Biol Chem 1984, 259:9799-9804.
29. Nieuwenhuis H.K., van Ouosterhout J.J.G., Rozemuller E., van Iwaarden F., Sixma J.J. Studies with a monoclonal antibody against activated platelets. Blood 1987, 70:838-845.
30. Hersel U., Dahmen C., Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003, 24:4382-4415.
31. Yang Z.L., Tu Q.F., Wang J., Lei X.J., He T.T., Sun H., et al. Bioactive plasma-polymerized bipolar films for enhanced endothelial cell mobility. Macromol Biosci 2011, 11:797-805.
32. Tanaka M., Takayama A., Ito E., Sunami H., Yamamoto S., Shimomura M. Effect of pore size of self-organized honeycomb-patterned polymer films on spreading, focal adhesion, proliferation, and function of endothelial cells. J Nanosci Nanotechnol 2007, 7:763-772.
33. 2 nanotube surfaces. Nano Lett 2008, 8:786-793.
34. Madri J.A., Stenn K.S. Aortic endothelial cell migration. I. Matrix requirements and composition. Am J Pathol 1982, 106:180-186.
35. Avci-Adali M., Paul A., Ziemer G., Wendel H.P. New strategies for in vivo tissue engineering by mimicry of homing factors for self-endothelialisation of blood contacting materials. Biomaterials 2008, 29:3936-3945.
36. McCormick C., Wadsworth R.M., Jones R.L., Kennedy S. Prostacyclin analogues: the next drug-eluting stent?. Biochem Soc Trans 2007, 35:910-911.
37. Sneddon J.M., Vane J.R. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A 1988, 85:2800-2804.
38. Rzucidlo E.M., Martin K.A., Powell R.J. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg 2007, 45(Suppl. A):A25-A32.
39. Newby A.C., Southgate K.M., Assender J.W. Inhibition of vascular smooth muscle cell proliferation by endothelium-dependent vasodilators. Herz 1992, 17:291-299.
40. Ward M.R., Stewart D.J., Kutryk M.J. Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives. Catheter Cardiovasc Interv 2007, 70:983-998.
41. Hardhammar P.A., van Beusekom H.M., Emanuelsson H.U., Hofma S.H., Albertsson P.A., Verdouw P.D., et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996, 93:423-430.
42. Vrolix M.C.M., Legrand V., Reiber J.H.C., Grollier G., Schalij M.J., Brunel P., et al. Heparin-coated wiktor stents in human coronary arteries (MENTORTrial). Am J Cardiol 2000, 86:385-389.
43. ® - no influence on restenosis or clinical outcome. Eur Heart J 2001, 22:1808-1816.
44. Rubin H. Serine protease inhibitors (SERPINS): where mechanism meets medicine. Nat Med 1996, 2:632-633.
45. Yang Z., Birkenhauer P., Julmy F., Chickering D., Ranieri J.P., Merkle H.P., et al. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J Control Release 1999, 60:269-277.
46. Clowes A.W., Karnowsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977, 265:625-626.
47. Kohno M., Yokokawa K., Yasunari K., Minami M., Kano H., Mandal A.K., et al. Heparin inhibits human coronary artery smooth muscle cell migration. Metabolism 1998, 47:1065-1069.
48. Clowes A.W., Clowes M.M. Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res 1986, 58:839-845.
49. Bartorelli A.L., De Cesare N.B., Kaplan A.V., Fabbiocchi F., Montorsi P., Squadroni L., et al. Local heparin delivery prior to coronary stent implantation: acute and six-month clinical and angiographic results. Cathet Cardiovasc Diagn 1997, 42:313-320.
50. Camenzind E., Kint P.P., Di Mario C., Jürgen L., Giessen W., Boersma E., et al. Intracoronary heparin delivery in humans. Acute feasibility and long-term results. Circulation 1995, 92:2463-2472.
51. Loubeyre C., Morice M.C., Lefevre T., Piechaud J.F., Louvard Y., Dumas P. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. J Am Coll Cardiol 2002, 39:15-21.
52. Kamath K.R., Barry J.J., Miller K.M. The Taxus drug eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006, 58:412-436.
53. Puskas J.E., Munoz-Robledo L.G., Hoerr R.A., Foley J., Schmidt S.P., Evancho-Chapman M., et al. Drug-eluting stent coatings. WIREs Nanomed Nanobiotech 2009, 1:451-462.
54. Cutlip D.E., Baim D.S., Ho K.K.L., Popma J.J., Lansky A.J., Cohen D.J., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001, 103:1967-1971.
55. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
56. Pendyala L., Jabara R., Robinson K.A., Chronos N.A. Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing. J Interv Cardiol 2009, 22:37-48.
57. Wiemer M., Butz T., Schmidt W., Schmitz K.-P., Horstkotte D., Langer C. Scanning electron microscopic analysis of different drug eluting stents after failed implantation: from nearly undamaged to major damaged polymers. Catheter Cardiovasc Interv 2009, 75:905-911.
58. Yang Z.L., Wang X.N., Wang J., Yao Y., Sun H., Huang N. Pulsed-plasma polymeric allylamine thin films. Plasma Process Polym 2009, 6:498-505.
59. Waterhouse A., Yin Y.B., Wise S.G., Bax D.V., McKenzie D.R., Bilek M.M.M., et al. The immobilization of recombinant human tropoelastin on metals using a plasma-activated coating to improve the biocompatibility of coronary stents. Biomaterials 2010, 31:8332-8340.
60. Yin Y., Wise S.G., Nosworthy N.J., Waterhouse A., Bax D.V., Youssef H., et al. Covalent immobilisation of tropoelastin on a plasma deposited interface for enhancement of endothelialisation on metal surfaces. Biomaterials 2009, 30:1675-1681.
61. 2 nanotubes on endothelial function and smooth muscle proliferation. Biomaterials 2009, 30:1268-1272.
62. Smith B.S., Yoriya S., Grissom L., Grimes C.A., Popat K.C. Hemocompatibility of titania nanotube arrays. J Biomed Mater Res A 2010, 95A:350-360.